Sarepta mulls hunt for global partner for DMD drug; Merck pulls cholesterol drug;

Conversations on Twitter :

 @FierceBiotech: J&J's diabetes drug passes FDA panel test despite safety concerns. Story | Follow @FierceBiotech

@RyanMFierce: Another failure for tivantinib $ARQL. Ph2 in colon cancer after PhIII fiasco in lung cancer last year. | Follow @RyanMFierce

> Sarepta ($SRPT) is considering its strategy for finding a global partner for its hot experimental DMD drug, eteplirsen. Article

> KaloBios started a Phase II study for a monoclonal antibody to fight infection in patients with cystic fibrosis. Release

Medical Device News

 @FierceMedDev: Bayer gains FDA nod for long-use IUD. Story | Follow @FierceMedDev

@MarkHFierce: A Swiss Dx company focused on nanotech brought in $3M in new Series A financing. Article | Follow @MarkHFierce

 @DamianFierce: $LLY's jumping back on the companion diagnostics bandwagon with a new Dako partnership. Report | Follow @DamianFierce

> Medtronic hunts for expanded pacer indication with large study. Story

> As of July 1, Malaysia mandates device product registration. Item

Pharma News

@FiercePharma: Stada exec says board would entertain the right offer. Report | Follow @FiercePharma

 @AlisonBFierce: Manufacturers already shipped more than 128M doses of flu vaccine--nearly 95% of the 135M doses made this season. More | Follow @AlisonBFierce

> Merck yanks cholesterol drug Tredaptive from market. News

> Hamburg: FDA has power to require abuse deterrence in painkillers. Item

> Drugmakers run short of Tamiflu, vaccine as flu bug bites hard. Story

And Finally… Merck ($MRK) took the cholesterol pill Tredaptive off shelves after the med failed in big Phase III study. Item

 

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.